Free Trial
NASDAQ:IRTC

iRhythm Technologies Q3 2026 Earnings Date & Estimates

iRhythm Technologies logo
$108.66 -0.69 (-0.63%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$108.54 -0.13 (-0.12%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iRhythm Technologies is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET

What Analysts Expect from iRhythm Technologies in Q3 2026

iRhythm Technologies is expected to post earnings of $0.0155 per share on revenue of $222.23 million. In the same quarter a year earlier iRhythm Technologies reported -$0.06 per share on revenue of $192.88 million. iRhythm Technologies last reported on August 6, 2026, posting $0.58 per share and beating the -$0.04 consensus estimate. iRhythm Technologies has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0155
Expected Revenue
$222.23 million
Prior-Year EPS
-$0.06
Prior-Year Revenue
$192.88 million
Expected Revenue Growth
+15.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.58 (Beat by +$0.62)
Last Quarter Revenue
$224.17 million
EPS Beat Rate
6 of last 8 quarters

iRhythm Technologies Q3 2026 Earnings FAQ

iRhythm Technologies (NASDAQ:IRTC) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

iRhythm Technologies' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect iRhythm Technologies to post earnings of $0.0155 per share for Q3 2026.

The consensus revenue estimate for iRhythm Technologies is $222.23 million for Q3 2026.

iRhythm Technologies Earnings Headlines

Piper Sandler Initiates Coverage on iRhythm Technologies (NASDAQ:IRTC)
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
See More iRhythm Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRhythm Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRhythm Technologies and other key companies, straight to your email.

About iRhythm Technologies

iRhythm Technologies (NASDAQ:IRTC), Inc. is a digital health care company focused on ambulatory cardiac monitoring and the diagnosis of cardiac arrhythmias. The company combines wearable biosensor technology, cloud-based data analysis and clinical services to help physicians detect and manage irregular heart rhythms, including atrial fibrillation.

Its principal products include the Zio monitor portfolio, which is designed for extended, continuous electrocardiogram monitoring in an easy-to-use wearable format. iRhythm’s platform collects cardiac data outside the traditional clinical setting and uses proprietary algorithms and analysis tools to identify potentially significant events for review by health care professionals. The company also provides reporting and related support services that assist clinicians in interpreting monitoring results and making treatment decisions.

Founded in 2006 and headquartered in San Francisco, iRhythm primarily serves health care providers and patients in the United States. The company has also expanded availability of its technology and services into select international markets, including the United Kingdom. iRhythm’s products are used across cardiology, primary care and other clinical settings where extended monitoring can support the evaluation of suspected or previously undiagnosed arrhythmias.

View iRhythm Technologies Profile